《人绒毛膜促性腺激素的临床应用进展_王秀萍》由会员分享，可在线阅读，更多相关《人绒毛膜促性腺激素的临床应用进展_王秀萍（5页珍藏版）》请在金锄头文库上搜索。
1、8F5Z王秀萍,焦琳,郭红燕K1 F(HCG)55000 U/L 、1000 5000 U/L 、172836 d148128146pHCG,64C/,qr43.8%,M-,oC,zE;.l8p283s J .5LD,2006,5(10):1523-1524.188ISSN 1671-2838Pharm Care Res02010 Jun;10(3)E-mail PharmCR .cnPhn/Fax 86-21-65519829Liu Zhenyong, Xiao Delong, Dai Jiayuan.Clinical diagnosisand treatment forcryptorchi
2、sm in children(report of 283 ca-ses) J .J Clin Exp Med, 2006, 5(10):1523-1524.Chinesewith abstract in English.18 R,6.HCG38p8r4 J .D0,2003,7(6):437.Guo Lin,Jiang Yunxian.Clinical efficacy of human chorionicgonadotropin in treatment of 38 children with cryptorchism J .Anhui Med PharmJ,2003,7(6):437.Ch
3、inese.19 ),BS,u.Fwf4054 J .3D, 2005, 14(5):303-304.Huang Huixia, TianCong,Zhao Huiping.Observation of hu-man chorionicgonadotropinin treatment of sterility after sur-gery for varicocele:40 cases J .J ReprodMed,2005,14(5):303-304.Chinese.20 y+,c%,.HCG0Y J .5D,2001,3(4):233-234.Yu Jianjun,Wang Peile,W
4、uZhangmu, et al .Theinfluence ofhuman chorionic gonadotropin on ultrastructure of sperm ofpatientswith infertility J .Zhejiang Clin MedJ,2001,3(4):233-234.Chinese. 21 /,.、2005s J .v(DS),2006,4(1):53.ChenSue, Hu Aiping.Analysis of 200 cases of patients withinfertility J .J Yan an Univ (Med Sci), 2006
5、, 4(1):53.Chinese. 22 fg,UX,.HMGHCGx40s J .rB,2007,23(12):1068-1069.Zhang Cuihong,Qin Yanqin,Sun Yuhong.Application of hu-manmenopausalgonadotropincombined withhuman chorion-ic gonadotropin to stimulate ovulation in the treatment of 40patients with infertility J .Occupation Health, 2007, 23(12):1068
6、-1069.Chinese. 23 O,f,.-HCG_ZE1 J .D_5,2006,17(5):33-34.Fan Quming,Zhang Lei, He Lan, et al .The application andcomparison of the MEIA assay with colloidal gold for-HCG J .Med Lab Sci Clin, 2006,17(5):33-34.Chinese with ab-stract in English.l 2009-09-01 2010-04-07I 1-=Y/ZE5%v:4!#孟德胜,傅若秋,吴畏Te;(3),pV,
7、0=.E-mail:YT:l,E-mail:T400042i,+DvD04S1oM v:;4;!ZE;0ms| R 944.1, R 986DSM BcI| 1671-2838(2010)03-0189-03v:(minoxidil)V?(k)?(3?),i2%,M?C5%v:rTA2%v:,OAT1 。5%v:4!ZE、eZE#。1ZE1.1药品、仪器和试剂v:(Z0,|M20040602,c99.9%);5%v:4(+DvD04S1,|080310、080311、080312);(0),*0K,|070502);d=?(0),SCk4,|20070916);Y?(0),LK,|200706
8、13);q(sB,282K,|20050115);k4(sB。 UV8500,s;9(Z?SNK);BP-110S0?(0.1 mg,S)。1.2处方和制备1.2.1处方v:5g,d=?、a,75%Y?F100 ml。1.2.2制备|v:5 g,Fd=?、a75%Y?,P,F75%Y?100ml。2e2.1性状iA8。2.2鉴别|0.5 mlk5,FZ5mlq50 mg,F2 3min,vA。2.3含量测定2.3.1 紫外吸收光谱测定 |v:a,0.1 mol/LAidai,0.1 mol/LATb,200 350nmS=,v:A280 nmo)Kvl,)Z1b4o)l,Yv:。nm1。2.3.2线性关系考察|v:50mg100ml(下转第197页)1890Pharm Care Res2010 Jun;10(3);,.5%v:4!#
